Loading…
← CockpitCompetitor Analysis › CRL Charles River LaboratoriesOpen in the cockpit ↗

Charles River LaboratoriesCRLCompetitor analysis, valuation and peers

United States · USD·Health Care›Miscellaneous Commercial Services

Provides preclinical contract research services (drug safety testing, research models) supporting pharmaceutical and biotech drug development.

Momentum leader 97
Mkt cap
$16.0B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$404M
20-day average traded
Fwd P/E
26.2×
forward earnings
ROIC−WACC
-2.8 pp
WACC 10.9%
Hurdle
+19 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · USD$333.25
1D+0.3%
1W-2.8%
1M+5.6%
3M+14.3%
6M+113.6%
YTD+67.1%
1Y+104.8%
ATR %4.5%
Beta1.27
52w lowhigh12.2% off high

What Charles River Laboratories does

Provides preclinical contract research services (drug safety testing, research models) supporting pharmaceutical and biotech drug development.

Customers pay per study, often under fixed-fee contracts running months, for safety testing before a drug enters human trials, while research models (purpose-bred lab animals) are sold per unit. Because studies are booked in advance, the order backlog and biotech funding decide near-term volume.

Products and services

  • Research Models & Services
  • Discovery & Safety Assessment (preclinical testing)
  • Manufacturing Solutions (biologics testing)

Customers

  • Pharma/biotech companies (drug discovery/developme

Where it sits in the supply chain

  • Healthcare
  • Contract research organization (CRO)
  • Preclinical safety testing and research…

What could go right

  • Biopharma preclinical R&D outsourcing demand
  • Biologics/cell-gene therapy testing growth

What could go wrong

  • Biotech funding cycle sensitivity
  • Animal-welfare/regulatory scrutiny of research-model business

Moat: narrow (process know-how, regulatory licence, switching costs). Regulatory-accredited safety-testing facilities and specialized research-model supply create barriers to entry.

Headquarters: Wilmington, Massachusetts, USA · Founded: 1947 · Employees: 19,700

Named competitors

Charles River Laboratories at a glance

Size Charles River Laboratories (CRL) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $16.0B, the 567th largest of 3,085 United States companies the cockpit tracks. Shares closed at $333.25 on 18 Nov 2026.

Performance Over six months the shares gained 113.6%, against +30.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 15 in its peer set.

Growth Revenue fell 1.2% over the last twelve months (peer median +6.7%); the operating margin is 15.4% (peer median 3.6%).

Valuation It trades at 26.2× forward earnings against a peer median of 22.4× (4th most expensive of 9).

Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.8 points below its cost of capital (10.9% WACC).

Backlog Backlog (remaining performance obligations) was $675M at 26 Sep 2026, up 4% on a year earlier — 0.2 years of trailing revenue. Backlog detail →

Short interest Short interest is 6.2% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026CRL 210Peer median 132
Six months, rebased to 100: Charles River Laboratories against the median of its 14 peers (local-currency closes).

Charles River Laboratories financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.98B$4.02B$4.05B$4.13B$3.98B
Revenue growth—-1%-2%+4%—
Gross profit$1.33B$1.23B$1.27B$1.39B$1.32B
EBITDA$896M$919M$929M$975M$956M
Net income$40.2M-$144M$10.3M$475M$486M
Free cash flow$400M$518M$502M$365M$295M
Capital expenditure$223M$219M$233M$319M$325M
Total debt$2.85B$2.63B$2.78B$3.13B$3.15B

Quarterly statements and history in the cockpit →

Charles River Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%ICLRMEDP22684523PGNYFTRESLNOABISBCANLEVTOCSEVHTECXCRL6-month return →1-month return →
Up and to the right = strong over both horizons. Charles River Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×ICLRMEDP22684523PGNYFTRESBCEVHCRLRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Charles River Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%ICLRMEDP22684523PGNYFTREOABISBCEVHCRLGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Charles River Laboratories is the large dot.

Charles River Laboratories competitors and peer comparison

Head to head with its named competitors (CRL vs LH vs ICLR vs 2359.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%
Labcorp LH$30.1B+44%+6%11%19.3×14.5%
ICON ICLR$14.6B+70%+1%10%17.3×15.9%
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Pharmaron Beijing 3759.HK$9.65B+48%+24%14%20.8×n/a
Evotec EVT.DE$532M-46%-5%-15%n/an/a
Eurofins Scientific ERF.PA$16.4B+37%+3%12%22.1×12.9%

How Charles River Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Charles River Laboratories against its 14 peers (data as of 18 Nov 2026)
MeasureCRLPeer medianRank in peer set
1-month return+5.6%+0.6%5th highest of 15
6-month return+113.6%+30.4%2nd highest of 15
Distance from 52-week high-12.2%-18.4%7th highest of 15
Revenue growth (TTM)-1.2%+6.7%4th lowest of 12
Operating margin15.4%3.6%4th highest of 13
Forward P/E26.2×22.4×4th most expensive of 9
Growth the price implies (Req g, 7 yrs)25.6%15.9%3rd most demanding of 10
Growth delivered (Del g)+6.6%+15.2%4th lowest of 10
Hurdle (Req g minus delivered)+19.0 pp-1.2 pp3rd most demanding of 10
ROIC minus cost of capital-2.8 pp-4.7 pp5th highest of 10
EV / EBITDA20.8×17.6×3rd most expensive of 7
Net debt / EBITDA2.9×-0.8×3rd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Charles River Laboratories CRLUnited States$16.0B+114%-1%15%26.2×25.6%+6.6%
ICON ICLRUnited States$14.6B+70%+1%10%17.3×15.9%+24.2%
Medpace MEDPUnited States$18.1B+53%+20%21%33.5×22.3%+22.3%
WuXi XDC Cayman 2268.HKHong Kong$10.4B+20%+42%28%35.8×20.6%+126.4%
Eisai 4523.TJapan$9.36B+11%+11%6%26.6×10.7%+5.0%
Progyny PGNYUnited States$2.66B+41%+6%9%23.2×8.6%+30.2%
Fortrea FTREUnited States$1.98B+50%-3%2%21.6×31.9%+1.1%
Silence Therapeutics PLC Sponsored ADR SLNUnited States$1.23B+244%-98%-11,920%n/an/an/a
OmniAb OABIUnited States$741M+97%+91%-116%n/a60.6%-31.9%
SBC Medical SBCUnited States$645M+94%+7%40%11.7×-15.7%+6.7%
Adlai Nortye Ltd. Sponsored ADR ANLUnited States$610M-23%n/a-134%n/an/an/a
Evotec EVT.DEGermany$532M-46%-5%-15%n/an/an/a
Oculis OCSUnited States$456M-74%n/an/an/an/an/a
Evolent Health EVHUnited States$445M+2%+14%-1%9.2×14.0%+15.2%
Tectonic Therapeutic TECXUnited States$420M-27%n/an/an/an/an/a

Charles River Laboratories backlog

Charles River Laboratories reported $675M of remaining performance obligations at 26 Sep 2026, up 4% from a year earlier and down 4% from the previous quarter. That is 0.2 years of trailing revenue already under contract. Book-to-bill last quarter: 0.97.

Questions

Who are Charles River Laboratories's main competitors?
Named competitors: Labcorp (Covance CRO) (LH), ICON Plc (ICLR), Inotiv (private or unlisted), WuXi AppTec (2359.HK), Pharmaron (3759.HK), Evotec (EVT.DE). The cockpit's measured peer set (industry) also includes ICON (ICLR), Medpace (MEDP), WuXi XDC Cayman (2268.HK), Eisai (4523.T), Progyny (PGNY), Fortrea (FTRE).
Is Charles River Laboratories expensive compared with its peers?
On forward p/e it trades at 26.2× against a peer median of 22.4×, 4th most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Charles River Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +113.6% against +30.4% for the median peer; over one year +104.8%.
What is Charles River Laboratories's backlog?
Charles River Laboratories's remaining performance obligations (contracted revenue not yet recognised) were $675M at 26 Sep 2026, +4% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.